Endurant Capital Management’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Endurant Capital Management’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-145,380	Closed	-$596K	–	84
2021 Q3	$596K	Sell	145,380 -15,311	-10%	-$67K	0.14%	52
2021 Q2	$845K	Buy	+160,691	New	+$960K	0.23%	54

Other funds holding CYAD

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Endurant Capital Management's CYAD Position: Q4 2021 in Review

Endurant Capital Management sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q4 2021, closing a stake of 145,380 shares — an estimated $596K sold.

Endurant Capital Management first reported a position in CYAD in Q2 2021 and held it in 2 quarters. The position peaked at $845K in Q2 2021. 10 funds tracked by Wall St. Rank hold CYAD as of Q4 2021.

Endurant Capital Management reported no remaining Celyad Oncology SA American Depositary Shares position as of Q4 2021 after selling out during the quarter.
Endurant Capital Management sold 145,380 Celyad Oncology SA American Depositary Shares shares in Q4 2021, an estimated $596K.
Endurant Capital Management first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2021 and held it in 2 quarters.
Endurant Capital Management's Celyad Oncology SA American Depositary Shares position peaked at $845K in Q2 2021.
10 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q4 2021.

Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.